PrairieView Partners LLC Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)

PrairieView Partners LLC cut its position in Johnson & Johnson (NYSE:JNJGet Rating) by 23.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 2,393 shares of the company’s stock after selling 716 shares during the quarter. PrairieView Partners LLC’s holdings in Johnson & Johnson were worth $424,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. lifted its stake in Johnson & Johnson by 2.6% in the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after purchasing an additional 4,982,885 shares in the last quarter. State Street Corp raised its position in shares of Johnson & Johnson by 1.8% during the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after buying an additional 2,492,359 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Johnson & Johnson by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock valued at $7,576,867,000 after buying an additional 1,084,834 shares in the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $4,172,929,000. Finally, Legal & General Group Plc raised its position in shares of Johnson & Johnson by 5.8% during the 4th quarter. Legal & General Group Plc now owns 17,420,146 shares of the company’s stock valued at $2,980,062,000 after buying an additional 948,306 shares in the last quarter. 68.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JNJ. UBS Group lowered their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday. Citigroup lowered their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday. Credit Suisse Group raised their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Finally, Raymond James increased their target price on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $172.12 on Friday. The firm has a market cap of $452.92 billion, a PE ratio of 25.05, a price-to-earnings-growth ratio of 3.48 and a beta of 0.63. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The company’s fifty day simple moving average is $176.25 and its two-hundred day simple moving average is $174.36.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.48 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s payout ratio is 65.79%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.